Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1

Abstract Background In the PRISMS study, interferon beta-1a subcutaneously (IFN β-1a SC) reduced clinical and radiological disease burden at 2 years in patients with relapsing–remitting multiple sclerosis. The study aimed to characterize efficacy of IFN β-1a SC 44 μg and 22 μg three times weekly (ti...

Full description

Bibliographic Details
Main Authors: Anthony Traboulsee, David K. B. Li, Mark Cascione, Juanzhi Fang, Fernando Dangond, Aaron Miller
Format: Article
Language:English
Published: BMC 2018-09-01
Series:BMC Neurology
Subjects:
Relapsing–remitting multiple sclerosis
Clinical trials
Interferon-beta subcutaneously
Disability progression
MRI
No evidence of disease activity
Online Access:http://link.springer.com/article/10.1186/s12883-018-1145-x

Internet

http://link.springer.com/article/10.1186/s12883-018-1145-x

Similar Items